Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health

Provided By PR Newswire

Last update: Nov 17, 2022

Company Receives First Major Purchase Order in Saudi Arabia

TORRANCE, Calif., Nov. 17, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has been issued a Registration Certificate from the Registration Committee for Pharmaceutical Companies & their Products of the Qatar Ministry of Public Health granting marketing authorization for the commercial distribution and sale of Endari® in the country. The company also announced that it received its first major purchase order from its distributor in the Kingdom of Saudi Arabia, where Endari® is available on an early access basis only.